Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | Director | March 31, 2025 | April 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date March 31, 2025 · Filed April 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.58 · Expires 2035-03-31 | Direct | 50,000 |
Reported balance
After 2025-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-31 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests in three equal annual installments beginning on March 31, 2026 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three equal annual installments beginning on March 31, 2026
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2025 Filed Apr 3, 2025 01:46 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001731122-25-000516 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-03-31 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on March 31, 2026 Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 11:03 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001731122-24-000293 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-02-20 F1 · derivative.exercise_date: Options vest in equal installments over three years from the grant date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0001731122-23-000581 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-31 F1 · derivative.exercise_date: Options vest in equal instalments over three years from the grant date Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:10 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001731122-22-001143 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-27 Read SEC document |
| May 25, 2022 Filed May 28, 2022 00:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001731122-22-001013 · ownership.xml · derivative · entry 3 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options subject to this grant vested quarterly over a three-year period commencing on April 2, 2015. Read SEC document |
| May 25, 2022 Filed May 28, 2022 00:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | SaleCommon Stock | 50,000 | $9.06 | $453,000.00 |
DisclosureSEC source: 0001731122-22-001013 · ownership.xml · nonDerivative · entry 2 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,306,458 Read SEC document |
| May 25, 2022 Filed May 28, 2022 00:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 50,000 | $0.92 | $46,000.00 |
DisclosureSEC source: 0001731122-22-001013 · ownership.xml · nonDerivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,356,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:22 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001731122-21-001294 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-08-02 Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:29 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000016 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-30 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000018 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Read SEC document |
| October 01, 2018 Filed Oct 9, 2018 20:42 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010620 · s113196_form4.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 21:23 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001615774-16-007388 · s104218_form4.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-09-22 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.